network member

New Jersey

About Network Member

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
Cancer areas:Basket
AdventHealth Orlando
CARTI
John Theurer Cancer Center at Hackensack Meridian Health
Meritus Center for Clinical Research / John R. Marsh Cancer Center
Salinas Valley Health
University of Louisville / James Graham Brown Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)
Cancer areas:Bladder
Froedtert & the Medical College of Wisconsin
John Theurer Cancer Center at Hackensack Meridian Health
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Rochester Medical Center - Wilmot Cancer Institute
Vanderbilt-Ingram Cancer Center
Virginia Commonwealth University
Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Columbia University Irving Medical Center
Dana-Farber Cancer Institute
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
John Theurer Cancer Center at Hackensack Meridian Health
Moores Cancer Center at UC San Diego Health
Penn Medicine Abramson Cancer Center
The Ohio State University
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Weill Cornell Medicine
Winship Cancer Institute of Emory University
Yale Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Currently Enrolling

BTCRC-LYM20-463

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Cancer areas:Lymphoma
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GI16-288

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288
Cancer areas:Colorectal
Cleveland Clinic Cancer Center
Knight Cancer Institute at Oregon Health & Science University
Rutgers Cancer Institute of New Jersey
Sylvester Comprehensive Cancer Center at the University of Miami
The Ohio State University
University of Kansas Medical Center
Enrollment Closed

HCRN-GU16-287

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Rutgers Cancer Institute of New Jersey
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vanderbilt-Ingram Cancer Center
Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Summit Health Cancer Center
University of Illinois Cancer Center
University of Virginia Cancer Center
Enrollment Closed

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Michigan State University
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI15-067

A phase II study to evaluate the efficacy of liposomal irinotecan in combination with oxaliplatin, leucovorin, and 5-fluorouracil for patients with locally advanced pancreatic carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067
Cancer areas:Pancreatic
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
Cancer areas:Liver and Bile Duct
DHR Health
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN19-396

A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select IIIA [T3N1, T4N0-1] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Penn State Cancer Institute
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
Summit Health Cancer Center
The Ohio State University
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center